ARVN
Price:
$24.4
Market Cap:
$1.68B
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatmen...[Read more]
Industry
Biotechnology
IPO Date
2018-09-27
Stock Exchange
NASDAQ
Ticker
ARVN
According to Arvinas, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.60. This represents a change of -42.34% compared to the average of -7.98 of the last 4 quarters.
The mean historical PE Ratio of Arvinas, Inc. over the last ten years is -15.49. The current -4.60 PE Ratio has changed 2.87% with respect to the historical average. Over the past ten years (40 quarters), ARVN's PE Ratio was at its highest in in the June 2017 quarter at -1.14. The PE Ratio was at its lowest in in the September 2021 quarter at -21.88.
Average
-15.49
Median
-16.92
Minimum
-30.04
Maximum
-2.92
Discovering the peaks and valleys of Arvinas, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 646.01%
Maximum Annual PE Ratio = -2.92
Minimum Annual Increase = -78.90%
Minimum Annual PE Ratio = -30.04
Year | PE Ratio | Change |
---|---|---|
2023 | -6.22 | -7.08% |
2022 | -6.69 | -70.14% |
2021 | -22.42 | -25.36% |
2020 | -30.04 | 37.93% |
2019 | -21.78 | 646.01% |
2018 | -2.92 | -78.90% |
2017 | -13.84 | -30.81% |
The current PE Ratio of Arvinas, Inc. (ARVN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-11.78
5-year avg
-17.43
10-year avg
-15.49
Arvinas, Inc.’s PE Ratio is less than C4 Therapeutics, Inc. (-3.44), less than Monte Rosa Therapeutics, Inc. (-3.11), greater than Nurix Therapeutics, Inc. (-8.82), less than Foghorn Therapeutics Inc. (-4.49), less than Relay Therapeutics, Inc. (-2.57), greater than Stoke Therapeutics, Inc. (-7.92), less than Pliant Therapeutics, Inc. (-4.19), less than Black Diamond Therapeutics, Inc. (-3.70), less than Shattuck Labs, Inc. (-2.08), greater than Kymera Therapeutics, Inc. (-21.01), greater than Ultragenyx Pharmaceutical Inc. (-8.17), greater than Crinetics Pharmaceuticals, Inc. (-15.40), greater than Revolution Medicines, Inc. (-13.31), greater than Kura Oncology, Inc. (-9.19), less than Century Therapeutics, Inc. (-0.91),
Company | PE Ratio | Market cap |
---|---|---|
-3.44 | $374.42M | |
-3.11 | $349.21M | |
-8.82 | $1.50B | |
-4.49 | $416.63M | |
-2.57 | $835.47M | |
-7.92 | $773.92M | |
-4.19 | $782.51M | |
-3.70 | $305.13M | |
-2.08 | $167.05M | |
-21.01 | $2.89B | |
-8.17 | $5.09B | |
-15.40 | $4.03B | |
-13.31 | $6.99B | |
-9.19 | $1.48B | |
-0.91 | $123.69M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arvinas, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arvinas, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Arvinas, Inc.'s PE Ratio?
How is the PE Ratio calculated for Arvinas, Inc. (ARVN)?
What is the highest PE Ratio for Arvinas, Inc. (ARVN)?
What is the 3-year average PE Ratio for Arvinas, Inc. (ARVN)?
What is the 5-year average PE Ratio for Arvinas, Inc. (ARVN)?
How does the current PE Ratio for Arvinas, Inc. (ARVN) compare to its historical average?